CHICAGO HIGHLIGHTS 2024 – LUNG ROUNDTABLE DISCUSSION: KRYSTAL-12
OR
Chair
Dr. Barb Melosky
Panelists
Dr. Rosalyn Juergens
Dr. Peter Ellis
This program has been made possible through unrestricted support from Pfizer
Studies/trials discussed:
- Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-12)
- A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)
